User login
At the NORD Rare Diseases and Orphan Products Summit in Arlington, Virginia, on October 21-22, personalized or precision medicine—and its potential impact on the millions of Americans who have rare diseases—will be a recurring theme. Barbara Conley, MD, Associate Director of the National Cancer Institute’s Cancer Diagnosis Program, will discuss precision medicine initiatives at NCI.
Joshus Denny, MD, MS, Associate Professor of Medicine and Bioinformatics at Vanderbilt University and a member of the NIH Precision Medicine Initiative Working Group, will discuss the report recently released by that group and plans for moving forward with the PMI initiative.
Other topics of particular timeliness at the NORD Summit this year include promoting earlier diagnosis for patients, rare cancer treatment challenges, and advances and ethical considerations related to newborn screening. The NORD Summit is open to all, and online registration is available through the NORD website.
At the NORD Rare Diseases and Orphan Products Summit in Arlington, Virginia, on October 21-22, personalized or precision medicine—and its potential impact on the millions of Americans who have rare diseases—will be a recurring theme. Barbara Conley, MD, Associate Director of the National Cancer Institute’s Cancer Diagnosis Program, will discuss precision medicine initiatives at NCI.
Joshus Denny, MD, MS, Associate Professor of Medicine and Bioinformatics at Vanderbilt University and a member of the NIH Precision Medicine Initiative Working Group, will discuss the report recently released by that group and plans for moving forward with the PMI initiative.
Other topics of particular timeliness at the NORD Summit this year include promoting earlier diagnosis for patients, rare cancer treatment challenges, and advances and ethical considerations related to newborn screening. The NORD Summit is open to all, and online registration is available through the NORD website.
At the NORD Rare Diseases and Orphan Products Summit in Arlington, Virginia, on October 21-22, personalized or precision medicine—and its potential impact on the millions of Americans who have rare diseases—will be a recurring theme. Barbara Conley, MD, Associate Director of the National Cancer Institute’s Cancer Diagnosis Program, will discuss precision medicine initiatives at NCI.
Joshus Denny, MD, MS, Associate Professor of Medicine and Bioinformatics at Vanderbilt University and a member of the NIH Precision Medicine Initiative Working Group, will discuss the report recently released by that group and plans for moving forward with the PMI initiative.
Other topics of particular timeliness at the NORD Summit this year include promoting earlier diagnosis for patients, rare cancer treatment challenges, and advances and ethical considerations related to newborn screening. The NORD Summit is open to all, and online registration is available through the NORD website.
